This article is more than 5 years old. Information may no longer be current.
Hydrus reduces IOP in comparison trial
Click Here to Manage Email Alerts
WASHINGTON — Data from the COMPARE trial for the Hydrus microstent vs. two iStents as a stand-alone treatment for open-angle glaucoma showed some advantages for the Hydrus, according to a speaker here.
“In the comparison, Hydrus was statistically superior in lowering the medication count, the number of eyes that were completely medication free at a year, the number of eyes in terms of preventing them from requiring three or more medications, and then in addition reducing the IOP by an additional 20%,” David F. Chang, MD, said at the American Society of Cataract and Refractive Surgery annual meeting.
The prospective, multicenter, randomized COMPARE trial included patients with mild to moderate open-angle glaucoma who were taking two or more medications. Patients were randomly assigned 1:1 to either the Hydrus (Ivantis) group or the two iStent (Glaukos) group. Seventy-five patients were in the Hydrus group and 77 in the two iStent group.
At 12 months, 46.6% of Hydrus patients were required to take no medication compared with 24% of iStent patients, a statistically significant difference, Chang said.
“How many people remained on three or more medications? There were a number of these, and here again it was three times more likely with the two iStents that the patient would still be on that many medications,” he said.
Additionally, 72.6% of patients in the Hydrus group had a sustained reduction of at least one medication and at least a 20% drop in IOP compared with 46.7% of iStent patients, a statistically significant difference, he said.
The iStent is FDA approved for use with cataract surgery to reduce IOP in adults with mild to moderate open-angle glaucoma; Ivantis has submitted a premarket approval application to the FDA for the Hydrus to lower IOP in open-angle glaucoma. – by Robert Linnehan
References:
Chang DF. COMPARE Trial. Prospective, multicenter, randomized comparison of Hydrus versus two iStents for standalone treatment of OAG. Presented at: American Society of Cataract and Refractive Surgery annual meeting; April 13-17, 2018; Washington.
Comparing effectiveness of the Hydrus microstent to two iStents to lower IOP in phakic eyes (COMPARE). NCT02023242. https://www.clinicaltrials.gov/ct2/show/NCT02023242?term=hydrus&rank=5.
Disclosures: Chang reports he is a consultant for Ivantis. Ivantis is the sponsor of the trial.